Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly
Pfizer was all set to acquire New York City-based Metsera for $4.9 billion, but Novo Nordisk stepped in with an unexpected counteroffer of $6.5 billion. Both companies hope to add Metsera's drugs to their GLP-1 portfolios.
Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk
The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns.
Clinical trials paused due to heart patient’s hospitalization
Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury.
New drug recall includes more than 140K bottles of popular statin
According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

Half-dose DOAC improves outcomes after LAAO

The new-look anticoagulation strategy was associated with a significant reduction in adverse outcomes.

FDA announces recall of 2 hypertension medications

The affected batches were distributed from October 2018 to December 2020.

The pandemic's impact on statin prescriptions

The analysis, published in Circulation: Cardiovascular Quality and Outcomes, included more than 20,000 patient encounters.

Web-based resource helps consumers make key decisions about statin use

Researchers tracked data from 500 participants who completed a web-based evaluation in their home.

ASCVD events, death more likely when patients ignore statin recommendations

These findings have important clinical implications for ASCVD prevention.

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine.

Rivaroxaban limits adverse limb and cardiovascular events in surgically treated PAD patients

Rivaroxaban was associated with more bleeding than a placebo, researchers observed, but the overall incidence of such events was still low.

Statin use prior to hospitalization linked to lower COVID-19 mortality

The trend is particularly noticeable in patients with a history of CVD or hypertension.

Pharmaceutics

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Novo Nordisk, Pfizer enter bidding war for biotech startup—and it is getting ugly

Nearly 600K bottles of blood pressure drug recalled due to carcinogen risk

Clinical trials paused due to heart patient’s hospitalization

New drug recall includes more than 140K bottles of popular statin